Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000902664-25-002560·Biodexa Pharmaceuticals Plc
Schedule 13G ownership disclosure
BIODEXA PHARMACEUTICALS PLC SPONSORED
Ordinary Shares, nominal value 0.00005 GBP per share · CUSIP: 59564R807
Event date: 2025-05-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Cavalry Fund I LP
Shares: 1,460,870,000.00 · Class: 5.7%
- C/M Capital Partners, LP
Shares: 1,460,870,000.00 · Class: 5.7%
- Cavalry Investment Fund LP
Shares: 74,830,000.00 · Class: 0.3%
- Cavalry Fund I Management LLC
Shares: 74,830,000.00 · Class: 0.3%
- Mercer Street Global Opportunity Fund, LLC
Shares: 291,520,000.00 · Class: 1.1%
- Mercer Street Capital Partners, LLC
Shares: 291,520,000.00 · Class: 1.1%
- Thomas Walsh
Shares: 1,535,700,000.00 · Class: 6.0%
- Jonathan Juchno
Shares: 1,752,390,000.00 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002560
- Form type
- SCHEDULE 13G
- Filer
- Biodexa Pharmaceuticals Plc
- CIK
- CIK 1643918
- Filed
- May 28, 2025
- Reporting period
- May 20, 2025
- Description
- Schedule 13G beneficial ownership